Cellectis (CLLS) Capital Expenditures Growth (1y) (2016 - 2026)
Cellectis (CLLS) Capital Expenditures Growth (1y) (2016 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Capex Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
- |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
- |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
- |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
227.76% |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Cellectis |
17.40 Bn |
17.21 Bn |
- |
32.91% |
| Date | Value |
|---|
| Mar 31, 2026 |
32.91% |
| Dec 31, 2025 |
-59.25% |
| Sep 30, 2025 |
-51.99% |
| Jun 30, 2025 |
70.62% |
| Mar 31, 2025 |
-81.19% |
| Dec 31, 2024 |
479.17% |
| Sep 30, 2024 |
-147.45% |
| Jun 30, 2024 |
-284.44% |
| Mar 31, 2024 |
-2.35% |
| Dec 31, 2023 |
-81.97% |
| Sep 30, 2023 |
29.91% |
| Jun 30, 2023 |
70.49% |
| Mar 31, 2023 |
65.97% |
| Dec 31, 2022 |
-87.99% |
| Sep 30, 2022 |
90.29% |
| Jun 30, 2022 |
83.21% |
| Mar 31, 2022 |
92.36% |
| Dec 31, 2021 |
-49.11% |
| Sep 30, 2021 |
27.18% |
| Jun 30, 2021 |
61.01% |
